Proton MR spectroscopy correlates diffuse axonal injury with post-concussive symptoms in mild traumatic brain injury

Ivan I Kirov1, Assaf Tal1, James S Babbs1, Joseph Reaumue1, Tamara Bushnik1, Teresa A Ashman1, Steven Flanagan2, Robert Grossman1, and Oded Gonen1

1Radiology, New York University, New York, NY, United States, 2Rusk Institute of Rehabilitation Medicine, New York University, New York, NY, United States

TARGET AUDIENCE: MR application scientists/neurologists/radiologists interested in imaging markers for traumatic brain injury.

PURPOSE: There are no established biomarkers for mild traumatic brain injury (mTBI), in part because post-concussive symptoms (PCS) are subjective and conventional imaging is typically unremarkable. To test whether diffuse axonal injury (DAI) quantified with three-dimensional (3D) proton magnetic resonance spectroscopic imaging (1H-MRSI) correlated with patients’ PCS we studied 26 mTBI patients (mean Glasgow Coma Scale score (GCS) of 14.7) and 13 controls.

METHODS: The previously described 26 patient cohort1 was recruited serially based on history of closed head trauma, GCS score of 13-15, loss of consciousness of 30 minutes or less and post-traumatic amnesia under 24 hours. 13 age- and gender-matched healthy controls were also enrolled. Based on a review of 11 original research articles, a 2004 report by the World Health Organization Collaborating Center Task Force on mTBI classified the following as the most common acute self-reported mTBI symptoms: headache, dizziness, sleep disturbance, memory problems and blurred vision2. On scan day, patients completed a ‘yes’ or ‘no’ questionnaire whether they were experiencing any of these five symptoms, which they attributed to the trauma. Patients reporting at least one symptom group were deemed “PCS-positive”, whereas the rest were defined as “PCS-negative”.

All measurements and post-processing have been previously described1. In short, the 10x8x4.5=360 cm3 1H-MRSI volume of interest (VOI) (6 slices, 80 voxels per slice, each 0.75 cm3) was image-guided over the corpus callosum, as shown in Fig. 1 and two averages were obtained. After segmentation of the MP-RAGE images, the resultant cerebro-spinal fluid (CSF), gray matter (GM) and white matter (WM) masks were co-registered with the 1H-MRSI grid using in-house software, yielding their volume in every voxel in each subject. Absolute metabolite amounts of N-acetylasparte (NAA), creatine (Cr), choline (Cho) and myo-inositol (mI) were obtained using phantom replacement with correction for differences in T1 and T2 relaxation time. Global GM and WM concentrations were calculated for each metabolite using linear regression3. Two-way analysis of variance was used to compare each patient group to the cohort of controls matched to them in terms of each metabolite within GM and WM. The indicator variable identifying subjects that were matched to each other was included as a blocking factor. The error variance was allowed to differ across comparison groups. The Cohen’s d statistic was calculated as a measure of effect size for the difference between each patient group and the cohort of controls matched to them in terms of each metabolite within GM and WM.

RESULTS: There were no statistically differences in the GCS score or time from injury between the PCS-positive (n=15) and the PCS-negative (n=11) groups. None of the concentrations of any metabolite either in GM or WM were different between the PCS-negative patients and their age- and gender-matched controls (n=8). PCS-positive patients had normal GM NAA, Cr, Cho and mI, as well as normal WM Cr, Cho and mI, but significantly lower WM NAA than their age- and gender-matched controls (n=12): 7.0±0.6 versus 7.9±0.5 mM, p=0.0007, as shown in Fig. 2. Based on its Cohen’s d value of 1.65, the effect size of this difference is defined as ‘large’.

DISCUSSION: DAI is the hallmark TBI injury, thought to occur across the entire clinical TBI spectrum, including patients with GCS=15 and normal neuroimaging. To be able to detect it in this population we previously used two 1H-MRSI post-processing approaches developed specifically for increased sensitivity to diffuse disease3,4. We found decreased global WM NAA, but no other metabolic abnormalities either in WM or GM, and these results were interpreted as DAI without glial involvement or cell body injury. Here we report that the WM NAA decrease can be entirely ascribed to those patients who reported at least one PCS at the time of scanning. The association was robust statistically (Cohen’s d = 1.65), even despite the relatively small sample sizes.

CONCLUSION: In cohorts representative of patients for whom there are no established radiological or clinical measures of outcome, global WM NAA levels were lower in PCS-positive patients, but were normal in the PCS-negative group. This indicates that global WM NAA is sensitive to the DAI sequelae underlying common subacute mTBI symptoms.

REFERENCES: